<DOC>
	<DOCNO>NCT02053493</DOCNO>
	<brief_summary>A randomized , double-blinded , placebo-controlled crossover study assess effect isosorbide mononitrate dose up-titration activity tolerance assess ( hip-worn , tri-axial ) accelerometry .</brief_summary>
	<brief_title>Nitrate 's Effect Activity Tolerance Heart Failure With Preserved Ejection Fraction</brief_title>
	<detailed_description>To evaluate whether isosorbide mononitrate increase daily activity assess 14-day averaged arbitrary accelerometry unit comparison placebo .</detailed_description>
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>Isosorbide-5-mononitrate</mesh_term>
	<mesh_term>Isosorbide Dinitrate</mesh_term>
	<mesh_term>Isosorbide</mesh_term>
	<criteria>1 . Age ≥ 50 year 2 . Symptoms dyspnea ( NYHA class IIIV ) without evidence noncardiac ischemic explanation dyspnea 3 . Ejection fraction ( EF ) ≥ 50 % determine image study within 12 month enrollment change clinical status suggest potential deterioration systolic function 4 . Stable medical therapy 30 day define : No addition removal ACE , Angiotensin receptor blocker ( ARBs ) , betablockers , calcium channel blocker ( CCBs ) aldosterone antagonists No change dosage ACE , ARBs , betablockers , CCBs aldosterone antagonists 100 % 5 . One follow within last 12 month Previous hospitalization heart failure ( HF ) radiographic evidence pulmonary congestion ( pulmonary venous hypertension , vascular congestion , interstitial edema , pleural effusion ) Catheterization document elevated filling pressure rest ( LVEDP≥15 PCWP≥20 ) exercise ( PCWP≥25 ) Elevated NTproBNP ( &gt; 400 pg/ml ) BNP ( &gt; 200 pg/ml ) Echo evidence diastolic dysfunction / elevate fill pressure ( least two ) E/A &gt; 1.5 + decrease E/A &gt; 0.5 valsalva Deceleration time ≤ 140 m Pulmonary vein velocity systole &lt; diastole ( PVs &lt; PVd ) sinus rhythm ) E/e'≥15 Left atrial enlargement ( ≥ moderate ) Pulmonary artery systolic pressure &gt; 40 mmHg Evidence leave ventricular hypertrophy LV mass/BSA ≥ 96 ( ♀ ) ≥ 116 ( ♂ ) g/m2 Relative wall thickness ≥ 0.43 ( ♂ ♀ ) [ ( IVS+PW ) /LVEDD ] Posterior wall thickness ≥ 0.9 ( ♀ ) 1.0 ( ♂ ) cm 6 . No chronic nitrate therapy infrequent ( ≤ 1x week ) use intermittent sublingual nitroglycerin within last 3 month 7 . Ambulatory ( wheelchair / scooter / walker / cane dependent ) 8 . HF primary factor limit activity indicate answer # 2 follow question : My ability active limit : 1 . Joint , foot , leg , hip back pain 2 . Shortness breath and/or fatigue and/or chest pain 3 . Unsteadiness dizziness 4 . Lifestyle , weather , I n't like active 9 . Body size allow wear accelerometer belt confirm ability comfortably fasten test belt provide screen process ( belt design fit person BMI 2040 Kg/m2 belt may fit person outside range ) 10 . Willingness wear accelerometer belt duration trial 11 . Willingness provide informed consent 1 . Recent ( &lt; 3 month ) hospitalization HF 2 . Hemoglobin &lt; 8.0 g/dl 3 . Glomerular filtration rate &lt; 20 ml/min/1.73 m2 recent clinical laboratory 4 . SBP &lt; 110 mmHg &gt; 180 mmHg consent 5 . Diastolic blood pressure &lt; 40 mmHg &gt; 100 mmHg consent 6 . Resting HR &gt; 110 bpm consent 7 . Previous adverse reaction nitrate necessitate withdrawal therapy 8 . Chronic therapy phosphodiesterase type5 inhibitor ( intermittent use phosphodiesterase type5 inhibitor erectile dysfunction allowable patient willing hold duration trial ) 9 . Regularly ( &gt; 1x per week ) swim water aerobics 10 . Significant COPD think contribute dyspnea 11 . Ischemia think contribute dyspnea 12 . Documentation previous EF &lt; 50 % 13 . Acute coronary syndrome within 3 month define electrocardiographic change biomarkers myocardial necrosis ( e.g . troponin ) appropriate clinical setting ( chest discomfort anginal equivalent ) 14 . Percutaneous coronary intervention , coronary artery bypass graft new biventricular pacing within past 3 month 15 . Primary hypertrophic cardiomyopathy 16 . Infiltrative cardiomyopathy ( amyloid ) 17 . Constrictive pericarditis tamponade 18 . Active myocarditis 19 . Complex congenital heart disease 20 . Active collagen vascular disease 21 . More mild aortic mitral stenosis 22 . Intrinsic ( prolapse , rheumatic ) valve disease moderate severe severe mitral , tricuspid aortic regurgitation 23 . Acute chronic severe liver disease evidence follow : encephalopathy , variceal bleeding , INR &gt; 1.7 absence anticoagulation treatment 24 . Terminal illness ( HF ) expect survival less 1 year 25 . Enrollment plan enrollment another therapeutic clinical trial next 3 month 26 . Inability comply plan study procedure 27 . Pregnant woman</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Heart Failure</keyword>
	<keyword>Preserved Ejection Fraction</keyword>
</DOC>